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Abstract
Purpose:Chemotherapy-induced apoptosis of immature hematopoietic cells is a major cause of anemia
and thrombocytopenia in cancer patients. Although hematopoietic growth factors such as erythropoietin
and colony-stimulating factors cannot prevent the occurrence of drug-inducedmyelosuppression, stem cell
factor (SCF) has been previously shown to protect immature erythroid and megakaryocytic cells in vitro
from drug-induced apoptosis. However, the effect of SCF in vivo as a single myeloprotective agent has never
been elucidated.
Experimental Design: The ability of SCF to prevent the occurrence of chemotherapy-induced anemia
and thrombocytopenia was tested in a mouse model of cisplatin-induced myelosuppression. To highlight
the importance of maintaining a continuous antiapoptotic signal in immature hematopoietic cells, we
compared two treatment schedules: in the first schedule, SCF administration was interrupted during
chemotherapy treatment and resumed thereafter, whereas in the second schedule, SCF was administered
without interruption for 7 days, including the day of chemotherapy treatment.
Results: The administration of SCF to cisplatin-treated mice could preserve bone marrow integrity,
inhibit apoptosis of erythroid andmegakaryocytic precursors, prevent chemotherapy-induced anemia, and
rapidly restore normal platelet production. Treatment with SCF increased the frequency of Bcl-2/Bcl-XL–
positive bonemarrow erythroid cells and sustained Akt activation inmegakaryocytes. Myeloprotection was
observed only when SCF was administered concomitantly with cisplatin and kept constantly present
during the days following chemotherapy treatment.
Conclusions: SCF treatment can prevent the occurrence of chemotherapy-induced anemia and
thrombocytopenia in mice, indicating a potential use of this cytokine in the supportive therapy of cancer
patients. Clin Cancer Res; 17(19); 6185–91. 2011 AACR.
Introduction
Chemotherapy-induced bone marrow damage results in
anemia and thrombocytopenia that threaten the patients’
quality of life and the overall efficacy of anticancer treat-
ments. Hematopoietic growth factors such as erythropoi-
etin and colony-stimulating factors are commonly used to
promote hematopoietic recovery following chemotherapy,
but they cannot prevent the occurrence of drug-induced
myelosuppression. Stem cell factor (SCF) is produced by
stromal cells of the bone marrow and binds the receptor
c-kit expressed on hematopoietic stem and progenitor cells
(1). It is essential for erythroid homeostasis, as mice
defective for SCF or its receptor c-kit display severe mac-
rocytic anemia and inefficient response to stress erythro-
poiesis (2–7). SCF administration has been shown to
stimulate hematopoiesis in rodents, primates, and humans
by increasing the number of bone marrow stem and
progenitor cells (8–10) and promote recovery after cyto-
toxic damage (11). Besides stimulating hematopoietic cell
expansion, SCF is a potent antiapoptotic factor for ery-
throid and megakaryocytic cells (12–15). In vitro, SCF can
prevent chemotherapy-induced apoptosis of immature ery-
throblasts and megakaryocytes, which are exquisitely vul-
nerable to cytotoxic agents (14, 15). In this report, we show
that SCF acts as a myeloprotective agent in vivo, being able
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to protect bone marrow cells from cisplatin-induced dam-
age. In particular, SCF protected bone marrow erythroid
(TER119þ) and megakaryocytic (CD41þ) precursors from
chemotherapy-induced depletion and prevented the occur-
rence of anemia and thrombocytopenia in the peripheral
blood of chemotherapy-treated mice. Importantly, only an
administration schedule that maintained a constant pres-
ence of SCF during and after chemotherapy treatment
could prevent bone marrow damage and consequent ane-
mia/thrombocytopenia, thus indicating the need for an
uninterrupted delivery of survival stimuli to achieve effec-
tive myeloprotection.
Materials and Methods
Mice treatment
Animal experiments were conducted according to the
National Animal Experimentation Guidelines (D.L.116/
92) upon approval of the experimental protocol by the
Institutional Animal Experimentation Committee. Six-
week-old C57/BL6 female mice weighing approximately
20 g were purchased from Jackson Laboratories and main-
tained with food and water ad libitum for the duration of
the studies. Mice were treated as follows: the "Control"
group received matched PBS injections, the "Cisplatin"
group received a single intraperitoneal dose of 7.5 mg/kg
cisplatin (Sigma Aldrich) at day 0, the "SCF" group received
50 mg/kg recombinant murine SCF (mSCF; Peprotech)
dissolved in PBS twice a day from days 1 to 7, "Inter-
rupted" mice received 7.5 mg/kg cisplatin at day 0 and 100
mg/kg mSCF at day 1 and once a day from days 1 to 7
(being SCF treatment interrupted during cisplatin admin-
istration), and "Constant" mice received cisplatin at day 0
and 50 mg/kg mSCF twice a day from days 0 to 7 (covering
also the day of cisplatin administration). SCF was admin-
istered subcutaneously.
Microscopy and flow cytometry
Bone marrow sections were prepared as follows: At the
end of the treatment, mice were sacrificed and femurs were
removed, fixed in buffered paraformaldehyde 10% for 24
hours, washed, and exposed to decalcifying solution (0.05
mol/L EDTA, 5NNaOH). Samples were deparaffinized and
hydrated, and staining reactions were then carried out on
6-mm-thick sections. To evaluate bone marrow cellularity,
histologic sections were stained with hematoxylin/eosin.
Terminal deoxynucleotidyl transferase–mediated dUTP
nick end labeling (TUNEL) staining was carried out with
the In Situ Cell Death Detection Kit (Roche Molecular
Biochemicals) according to the manufacturer’s instruc-
tions. For immunofluorescence analysis and May-
Gr€unwald-Giemsa staining, mice were sacrificed at the
end of the treatment, femurs were harvested, and marrow
flushed with a 23G (0.45  10 mm) syringe needle to
collect single-cell suspensions. For immunofluorescence
analysis of mouse bone marrow cells double positive for
CD41/phospho-Akt, TER119/Bcl-2, or TER119/Bcl-XL,
bone marrow cells were stained with phycoerythrin
(PE)-conjugated anti-CD41 (BD Pharmingen) or anti-
TER119 (eBioscience) and sorted with a FACSaria flow
cytometer (Becton Dickinson). Sorted cells were then
stained with primary antibodies against phospho-Akt (Cell
Signaling), Bcl-2 (clone C-21), or Bcl-XL (clone H5; Santa
Cruz Biotechnology). Alexa-Fluor 488 secondary antibody
was from Invitrogen Molecular Probes. Bone marrow sec-
tions and May-Gr€unwald-Giemsa–stained cells were ana-
lyzed with a Nikon Eclipse E1000 microscope equipped
with PlanFluor 40 dry objectives (numerical aperture:
0.75) and PlanApo 60 oil objectives (numerical aperture:
1.4), respectively (Nikon). Images were taken with a Nikon
DXM1200 RGB camera and the Nikon ACT-1 Software.
Immunofluorescence images were taken with an FV1000
confocal microscope (Olympus) equipped with a 60 oil
immersion objective and the Olympus Fluoview software.
To evaluate CD41þ and TER119þ bone marrow popu-
lations by flow cytometry, cells were harvested as
described earlier and stained with PE-conjugated anti-
CD41 or fluorescein isothiocyanate–conjugated anti-
TER119 (eBioscience). Samples were analyzed with a
FACSCanto flow cytometer equipped with FACSDiva
software.
Peripheral blood analyses
Peripheral blood was obtained from retro-orbital bleed-
ing ofmice treated as described earlier. Bleeding was carried
out at day 10 for hemoglobin analysis and at days 2 þ 10
for platelet analysis. Blood was dripped directly after
removal into tubes containing 0.5 mol/L EDTA. The
analysis of peripheral blood parameters was conducted
by a contract laboratory (AppiaLab) within 2 hours from
Translational Relevance
Chemotherapy-induced anemia and thrombocytope-
nia occur in a large portion of patients receiving mye-
losuppressive chemotherapy, leading to therapy-related
complications and treatment delay/reduction/discon-
tinuation that negatively influence patient survival.
The development of effective supportive strategies for
the treatment of chemotherapy-induced myelosuppres-
sion is therefore essential to improve the outcome of
both conventional and targeted antineoplastic therapies.
Stem cell factor (SCF) is mainly used in second-line
treatment regimens for mobilization-refractory patients.
Here, we show that SCF protects bone marrow from
chemotherapy-induced damage and prevents the occur-
rence of anemia and thrombocytopenia in the periph-
eral blood of treated mice. We also show for the first
time that the efficacy of SCF as a myeloprotective agent
depends on the schedule of administration.
The observation that SCF can protect erythroid and
megakaryocytic precursors in vivo provides a rationale
for a future use of this cytokine in preventing drug-
induced anemia and thrombocytopenia in cancer
patients.
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bleeding. For hemoglobin and platelet evaluation, mice
received 2 injections of 5 mg/kg cisplatin at days 0 and 4,
which was necessary to produce a constant decrease in
platelet number, avoiding rebound effects that occur after a
single chemotherapy treatment (16).
Statistical analysis
The statistical significance of results was calculated
using GraphPad Prism 4 (GraphPad Software Inc.; www.
graphpad.com) and analyzed by means of one-way
ANOVA and Bonferroni’s multiple comparison tests. A
Figure 2. Constant administration of SCF protects bone marrow from chemotherapy-induced damage. Mice were treated as described in Figure 1. A, TUNEL
staining of femur sections obtained at day 4 from the 5 groups of mice described earlier (left) and the number of TUNEL-positive cells assessed in 3
independent experiments carried out with 4 mice for each group (right). Images were taken with 40 magnification. One-way ANOVA and Bonferroni's
multiple comparison tests showed a statistical significance of ***, P < 0.001 between Cisplatin and Constant group mice. B, hematoxylin/eosin staining
of femur sections derived at day 7 from the 5 groups of mice described earlier (left) and absolute numbers of bone marrow (BM) cells extracted from
contralateral femurs and counted on a B€urker counting chamber (right). Images were taken with 40 magnification. Arrows on the Cisplatin panels
indicate clusters of dysplastic megakaryocytes. The experiment was repeated 4 times with 4 mice for each group. The comparison between Cisplatin
and Constant group mice with one-way ANOVA and Bonferroni's multiple comparison tests showed a statistical significance of **, P < 0.01.
Figure 1. Representation of the treatment schedule with SCF and cisplatin. Five groups of mice were treated as follows: the Control group received
matched PBS injections, the Cisplatin group received a single intraperitoneal dose of 7.5 mg/kg cisplatin at day 0 (bolt), the SCF group subcutaneously
received 50 mg/kg recombinant mSCF twice a day from days1 to 7, the Interrupted group received 7.5 mg/kg cisplatin at day 0 (bolt) and 100 mg/kg mSCF at
day 1 and once a day from days 1 to 7, and the Constant group received cisplatin at day 0 (bolt) and 50 mg/kg mSCF twice a day from days 0 to 7.
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value of P < 0.05 is represented by a single asterisk, P < 0.01
is indicated by a double asterisk, and P < 0.001 is indicated
by 3 asterisks.
Results and Discussion
To investigate whether SCF could protect bone marrow
cells from chemotherapy-induced destruction in vivo, we
induced myelosuppression in mice with a single dose of
cisplatin and administered SCF according to 2 treatment
schedules. In the cohort of mice indicated as Interrupted,
SCF was administered 24 hours before and 24 hours after
cisplatin injection and once daily for 6 additional days.
In the cohort of mice indicated as Constant, SCF was
administered 4 hours before and 4 hours after cisplatin
injection and then twice a day for 6 additional days. In the
Constant group, the schedule of administration ensured a
constant availability of SCF throughout the treatment
period, considering that SCF has an elimination half-life
of approximately 8 hours (17), whereas in the Interrupted
Figure 3. SCF specifically protects erythroid and megakaryocytic precursors from chemotherapy-induced depletion. A, May-Gr€unwald-Giemsa
staining of bone marrow cells extracted from the femurs of mice treated as described earlier (top) and numbers of megakaryocytes (bottom, left) and
erythroblasts (bottom, right) counted on May-Gr€unwald-Giemsa–stained slides derived from 4 independent experiments. Images were taken with
60 magnification. The difference in megakaryocyte numbers according to one-way ANOVA and Bonferroni's multiple comparison tests was statistically
significant with ***, P < 0.001 between Cisplatin and Constant group mice. The difference in erythroblast numbers according to one-way ANOVA and
Bonferroni's multiple comparison tests was statistically significant with *, P < 0.05 between Cisplatin and Constant group mice. B, flow cytometric analysis
of CD41 (top; MK, megakaryocytes) and TER119 expression (bottom; Erythroid, erythroid precursors) in bone marrow cells extracted at day 7 from C57/BL6
mice treated as described earlier. The panels show a representative set of results obtained from 2 independent experiments carried out with 6 mice for
each group.
Bartucci et al.
Clin Cancer Res; 17(19) October 1, 2011 Clinical Cancer Research6188
on January 14, 2015. © 2011 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst August 25, 2011; DOI: 10.1158/1078-0432.CCR-11-1232 
group, this condition was intentionally not fulfilled
(Fig. 1).
First, we analyzed bone marrow sections from control
mice (treated with PBS or with SCF alone) andmice treated
with cisplatin (in the presence or absence of SCF delivered,
according to the schedules described earlier) stained with
TUNEL to reveal the presence of apoptotic cells or with
hematoxylin/eosin to display bone marrow structure.
TUNEL-stained bonemarrow sections showed a high num-
ber of apoptotic cells both in mice treated with cisplatin
alone (36 6 per field) and in Interruptedmice (33 3 per
field), whereas in Constant mice, the number of dying cells
was significantly lower (9  2 per field; P < 0.001; Fig. 2A).
Upon hematoxylin/eosin staining, the bone marrow of
cisplatin-treated mice showed a strong hypoplasia with
myelofibrosis and clusters of dysplastic megakaryocytes
(Fig. 2B, left, arrows). The bonemarrowof Interruptedmice
was similar to that of mice treated with cisplatin alone,
indicating that an intermittent administration of SCF com-
promises the ability of this cytokine toprevent bonemarrow
destruction (Fig. 2B, left). These observations were con-
firmed by counting the absolute number of cells extracted
from mouse femurs (Fig. 2B, right). In contrast, bone
marrow structure and cell numbers of Constant mice
resembled those of mice treated with PBS, indicating that
constant administration of SCF protects bone marrow cells
from chemotherapy-induced damage. The analysis of May-
Gr€unwald-Giemsa–stained cells extracted from femurs of
mice treated as described earlier showed that megakaryo-
cytes and erythroblasts were significantlymore abundant in
Constant mice than in mice treated with cisplatin alone
(Fig. 3A; P < 0.001 and P < 0.05, respectively).
An analysis of bone marrow cells of the granulocytic
lineage on May-Gr€unwald-Giemsa–stained slides revealed
a significant decrease of granulocytic precursors in the
Cisplatin and the Interrupted samples, whereas SCF treat-
ment restored the levels of immature granulocytes in the
Constant group (data not shown). However, a massive
presence of mature granulocytes in the Cisplatin and the
Interrupted samples (likely represented by the long-lived
bonemarrow reservoir; ref. 18) rendered difficult to prove a
protective effect of SCF toward the granulocytic lineage.
The relative abundance of megakaryocytic and erythroid
cells was confirmed by fluorescence-activated cell-sorting
analysis of CD41þ and TER119þ cells in the bone marrow
of control and treated mice, respectively (Fig. 3B and
Supplementary Fig. S1).
SCF was previously shown to prevent chemotherapy-
induced apoptosis of purified human erythroblasts and
megakaryocytes (which were shown to represent the
preferential target of drug-induced damage within the
erythroid and megakaryocytic lineage, respectively) by
inducing an increase in antiapoptotic factors. Specifically,
SCF upregulates Bcl-2/Bcl-XL in erythroid precursors,
whereas in megakaryocytes, it increases Akt activation with
subsequent Bad phosphorylation (14, 15). To investigate
Figure 4. SCF activates
antiapoptotic pathways in
erythroid and megakaryocytic
cells in vivo. Immunofluorescence
analysis of Bcl-2, Bcl-XL, and
phospho-Akt (pAkt) in bone
marrow cells extracted from mice
treated as described in Figure 1.
Cells were sorted for the
expression of TER119 (Erythroid,
erythroid precursors) or CD41
(MK, megakaryocytes) and then
stained with anti-Bcl-2, anti-Bcl-
XL, or anti-phospho-Akt,
respectively. Images were taken
with an Olympus FV1000 confocal
microscope with 60
magnification and 6 zoom. The
experiment was repeated twice
with 6 mice for each group.
SCF Acts As a Myeloprotective Agent In Vivo
www.aacrjournals.org Clin Cancer Res; 17(19) October 1, 2011 6189
on January 14, 2015. © 2011 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst August 25, 2011; DOI: 10.1158/1078-0432.CCR-11-1232 
whether such antiapoptotic mechanisms were activated in
murine hematopoietic precursors upon SCF treatment in
vivo, we sorted cells positive for TER119 (erythroid pre-
cursors) or CD41 (megakaryocytic progenitors and mega-
karyocytes) from the bone marrow of mice treated with
vehicle, cisplatin, SCF only, or cisplatin plus SCF in the
Interrupted or Constant modality. Subsequent staining of
sorted bone marrow cells with anti-phosphorylated Akt
(for the CD41þ population) or with Bcl-2 or anti-Bcl-XL
(for the TER119þ population) showed an increased fre-
quency of Akt phosphorylation in CD41þ megakaryocytic
cells of Constant mice as compared with mice treated with
cisplatin alone (Fig. 4). Similarly, an increased number of
TER119þ bone marrow erythroid cells expressed Bcl-2 and
Bcl-XL in Constant mice as compared with mice treated
with cisplatin alone (Fig. 4). In both cases, Interruptedmice
did not differ significantly from mice treated with cisplatin
alone. These results indicate that only a continuous stim-
ulation with SCF can elicit antiapoptotic signals that act
through the mitochondrial pathway, thus preventing the
depletion of bone marrow erythroid and megakaryocytic
cells.
Then, we hoped to investigate the consequences of SCF-
inducedmyeloprotection on peripheral blood red cells and
platelets. To obtain a sustained decrease of hemoglobin
and platelets in the peripheral blood, mice were subjected
to 2 injections of cisplatin at days 0 and 4 of treatment,
respectively. Subsequent peripheral blood analyses
revealed that at day 10, hemoglobin levels of Constant
mice were significantly higher than those of cisplatin-trea-
ted animals (P < 0.01) and similar to those of vehicle-
treated controls, indicating that SCF efficiently prevented
the occurrence of cisplatin-induced anemia (Fig. 5A). An
assessment of platelet levels showed a progressive decrease
of platelet levels in the Cisplatin group and, to a lesser
extent, in the Interrupted group (Fig. 5B). Conversely,
platelet levels of the Constant group started to increase
after an initial reduction and, 10 days after the first che-
motherapy insult, reached the levels detected in control
animals (Fig. 5B). Altogether, these results indicate that a
constant administration of SCF can prevent the occurrence
of chemotherapy-induced anemia and thrombocytopenia
through a specific protection of immature erythroid and
megakaryocytic cells. Investigations are ongoing in our
laboratory to determine whether the protective effects
of SCF on the bone marrow may involve other immature
hematopoietic cells such as CD34þ hematopoietic pro-
genitors. A comprehensive analysis of pathways activat-
ed by SCF in immature hematopoietic cells conducted
by reverse-phase proteomic arrays shows activation of
multiple antiapoptotic pathways besides Bcl-2/Bcl-XL
increase and Akt phosphorylation (F. Pedini and A.
Zeuner, unpublished data), suggesting that a network
of signals activated by c-kit contributes to SCF-mediated
hematopoietic protection. The ability of SCF to activate
an extensive network of survival signals may explain the
multilineage antiapoptotic activity of this cytokine,
which would provide an advantage over more restricted
Figure 5. SCF prevents chemotherapy-induced decrease of hemoglobin
and platelets in the peripheral blood. A, hemoglobin (Hb) levels in the
peripheral blood of mice treated with SCF as described in Figure 1 and
with 5 mg/kg cisplatin at days 0 and 4. The blood was withdrawn at
day 10 by retro-orbital bleeding and analyzed with an automated
analyzer. The experiment was repeated 6 times with groups of 4 mice
each. One-way ANOVA analysis with Bonferroni's multiple comparison
tests showed a statistical significance of **, P < 0.01 between Cisplatin
and Constant group mice. B, platelet (PLT) numbers in the peripheral
blood of mice treated as in A. Mice belonging to the 5 treatment groups
were treated with 5 mg/kg cisplatin at days 0 and 4 (bolt). Blood was
obtained by retro-orbital bleeding at days 2 and 10 and analyzed with an
automated analyzer. The experiment was repeated 6 times with groups
of 4 mice each.
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growth factors (erythropoiesis- and granulopoiesis-
stimulating agents) currently used in the supportive
therapy of cancer patients. Although further in vivo
experiments with non-human primates would be useful
to confirm the myeloprotective activity of SCF, this
cytokine may find a future use to prevent drug-induced
anemia and thrombocytopenia in cancer patients with
tumors that do not rely on c-kit signaling for growth
and survival.
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